Neurocrine Biosciences to Highlight R&D Innovations at 2025 Event in San Diego

Neurocrine Biosciences Set to Showcase R&D Innovations at 2025 Event

Neurocrine Biosciences, Inc. announces its 2025 Research and Development (R&D) Day, scheduled for December 16, 2025, at 12:00 p.m. Eastern Time in San Diego. This pivotal event will serve as a platform for the company's management to elaborate on its ongoing transformation in R&D and to highlight its expanding neuroscience pipeline. Notably, Dr. John Krystal from Yale University, a respected figure in neuroscience, is set to participate, lending his expertise and insights to the discussions. Attendees will have the opportunity to engage with the content via a live webcast accessible on Neurocrine's official website, with a replay and presentation materials available for a month afterward.

As a leader in the biopharmaceutical industry, Neurocrine Biosciences is dedicated to developing innovative therapies for conditions affecting the neurological, neuroendocrine, and neuropsychiatric domains. For over 30 years, the company has focused on alleviating suffering through cutting-edge treatments, establishing a notable presence with FDA-approved medications for various disorders. These include therapies for tardive dyskinesia, chorea related to Huntington's disease, and hormonal disorders like classic congenital adrenal hyperplasia. Collaborative efforts with AbbVie have expanded the portfolio to include treatments for endometriosis and uterine fibroids, showcasing Neurocrine's commitment to addressing multifaceted health challenges.

The company’s robust pipeline, featuring several compounds in mid- to late-phase clinical development, reflects its strategic focus on scientific innovation. Neurocrine emphasizes its unique understanding of the intricate connections between brain and body systems, which is central to its mission of creating life-changing treatments. By continuing to advance its research capabilities and pipeline offerings, Neurocrine aims to ease the burden of debilitating conditions, striving for breakthroughs that significantly improve patient outcomes in the neuroscience landscape.

In addition to the upcoming R&D Day, stakeholders and interested parties are encouraged to explore Neurocrine's extensive research efforts and therapeutic advancements by visiting the company's website. The firm also maintains an active presence on social media platforms, including LinkedIn, X, and Facebook, to keep the community informed about its latest developments and initiatives. Neurocrine's commitment to neuroscience innovation positions it well for future advancements in the treatment of complex disorders.